SELLAS Life Sciences Group, Inc. (SLS) Stock Price & Analysis
SELLAS Life Sciences Group, Inc. (SLS) closed at USD 11.35 on Thursday, October 22, 2026, down 6.51% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.14; the Oct 22, 2026 session ranged USD 11.12–12.37 on volume of 6,509,122 shares. Market capitalization is $2.29B, with a 52-week range of USD 1.39–15.88 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SLS.md
Key facts (SLS)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 32.5 (range 30–35).
- Total return with dividends: 1Y +494.2% vs S&P 500 +14.9%; 5Y +30.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.05, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SLS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | $1.0M | $0K | — | — | — |
| Gross profit | $7.4M | $900K | $0K | — | — | — |
| Operating income | -$25.3M | -$42.0M | -$37.9M | -$31.5M | -$28.3M | -$35.2M |
| Net income | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M | -$32.5M |
| EPS (diluted) | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 | — |
| Gross margin | 97.4% | 90.0% | — | — | — | — |
| Operating margin | -332.8% | -4195.0% | — | — | — | — |
| Net margin | -272.4% | -4130.1% | — | — | — | — |
| Revenue growth | +300.0% | -86.8% | -100.0% | — | — | — |
| Cash + short-term investments | $21.4M | $17.1M | $2.5M | $13.9M | $71.8M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SLS)
P/B 16.6x · Earnings yield -1.42%
Analysts (SLS)
Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 32.5 (low 30, high 35).
Total return (dividends reinvested) (SLS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +494.2% | +30.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +497.9% | +5.4% |
| Volatility (annualized) | 105.6% | 103.2% |
| Max drawdown | -35.5% (Aug 2026→Oct 2026) | -94.5% (Nov 2021→Jan 2024) |
SLS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Merck (MRK) | “Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and s…” |
| Partner | Medicines | “In December 2020, we entered into an exclusive license agreement, or the 3D Medicines Agreement, with 3D Medicines Inc., or 3D Medicines, a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as the Company's next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diag…” |
| Competitor | AbbVie (ABBV) | “Principal competitors for AML broadly include companies with currently marketed products, such as AbbVie/Genentech (Venclexta), Pfizer (Mylotarg), Daiichi-Sankyo (Vanflyta), Rigel Pharmaceuticals (Rezlidhia), Syndax Pharmaceuticals (Revumenib) and Bristol Myers Squibb (Vidaza and Onureg), among others.” |
| Competitor | Pfizer (PFE) | “Principal competitors for AML broadly include companies with currently marketed products, such as AbbVie/Genentech (Venclexta), Pfizer (Mylotarg), Daiichi-Sankyo (Vanflyta), Rigel Pharmaceuticals (Rezlidhia), Syndax Pharmaceuticals (Revumenib) and Bristol Myers Squibb (Vidaza and Onureg), among others.” |
Quoted from the company's 10-K filed Mar 19, 2026.
SLS company outlook (results filed Aug 11, 2026)
- “Topline Data Expected in Q4 2026 – – Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, NY, August 11, 2026 -- SELLAS Life Sciences Group, Inc.”
- “At the same time, we are making meaningful progress with SLS009 in our ongoing Phase 2 frontline AML study, where dosing continues and enrollment is tracking ahead of industry standards, with topline data expected in the fourth quarter of 2026.”
- “Topline data expected in Q4 2026.”
Quoted word-for-word from the SEC 8-K results press release.
SLS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.05 | $-0.06 | -9.1% | $0 | 1 |
| Next quarter (ends Dec 2026) | $-0.05 | $-0.06 | -9.1% | $0 | 1 |
| Current fiscal year (ends Dec 2026) | $-0.20 | $-0.21 | -4.8% | $0 | 1 |
| Next fiscal year (ends Dec 2027) | $-0.10 | $-0.15 | -33.3% | $53.1M | 2 |
SLS options: expected move
Options price a move of about ±28.5% (±$3.22) by Nov 13, 2026, which includes earnings on Nov 11, 2026; the earnings reaction alone is priced at about ±18.2%. Over the last 8 reports the stock moved ±8.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 103.3% | ±12.4% |
| Nov 6, 2026 | 14 | 113.5% | ±18.6% |
| Nov 13, 2026 | 21 | 145.0% | ±28.5% |
| Nov 20, 2026 | 28 | 177.4% | ±40.0% |
| Nov 27, 2026 | 35 | 171.8% | ±42.8% |
| Dec 4, 2026 | 42 | 175.1% | ±47.7% |
| Dec 18, 2026 | 56 | 192.3% | ±58.3% |
| Jan 15, 2027 | 84 | 213.5% | ±76.9% |
30-day implied volatility 157% vs 91.1% realized over the last 30 trading days. Put/call ratio (volume) 0.27. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 11.35 |
|---|---|
| Change | ▼ 6.51% (down) |
| Previous Close | USD 12.14 |
| Open | USD 11.91 |
| Day Range | USD 11.12 – 12.37 |
| 52-Week Range | USD 1.39 – 15.88 |
| Volume | 6,509,122 shares |
| Market Cap | $2.29B |
| Exchange | NCM |
Technical Analysis (SLS)
Nexqual's technical model rates SLS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.96 (neutral) |
| vs SMA50 | Below (USD 12.42) |
| MACD | -0.2 (negative) |
Analyst Ratings (SLS)
Wall Street analysts rate SLS "Buy" based on 2 analysts, with a mean price target of USD 32.5 (range USD 30–35), per Nexqual as of October 23, 2026 at 09:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 32.5 |
| High Target | USD 35 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (SLS)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.05 ▼ miss |
| 2025-12-31 | USD -0.05 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.08 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (SLS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -39.63% |
| Debt / Equity | 0.01 |
| Current Ratio | 18.83 |
| Total Cash | $138.34M |
| Total Debt | $737,000 |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (SLS)
Nexqual rates SELLAS Life Sciences Group, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $138M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$28M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -40%, ROA -23.3% |
Ownership (SLS)
| Insider Ownership | +0.92% |
|---|---|
| Institutional Ownership | +37.07% |
| Shares Outstanding | 201.95M |
| Float | 201.15M |
| Short % of Float | +27.41% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Leadership (SLS)
SELLAS Life Sciences Group, Inc. is led by Angelos M. Stergiou M.D., ScD h.c., Founder, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:49 UTC.
| Founder, President, CEO & Director | Angelos M. Stergiou M.D., ScD h.c. |
|---|---|
| Senior VP & CFO | John Thomas Burns |
Major Backers & Investors (SLS)
Notable institutional backers of SELLAS Life Sciences Group, Inc. include Anson Funds Management LP, Fidelity, Jones Financial Companies, L.L.L.P., according to Nexqual as of October 23, 2026 at 09:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Anson Funds Management LP | 2.23% |
| Fidelity | 1.47% |
| Jones Financial Companies, L.L.L.P. | 1.14% |
| Susquehanna International Group, LLP | 1.02% |
| Dagco, Inc. | 0.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.46% |
| State Street | 6.44% |
| Vanguard Group | 5.14% |
| Geode Capital | 2.42% |
| Northern Trust | 0.8% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From SELLAS Life Sciences Group, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We are particularly focused on developing better treatments for AML, the lead indication for both GPS and SLS009, which will allow us to leverage our clinical development expertise in hematology/oncology and to build a single streamlined commercial infrastructure sufficient for both of our current product candidates.
Partnerships
- We expect this study will be used as the basis for submission of a Biologics License Application, or BLA, subject to a statistically significant and clinically meaningful trial outcome and agreement with the U.S.
- We expect this study will be used as the basis for a BLA submission, subject to a statistically significant and clinically meaningful trial outcome and agreement with the FDA.
Legal & Regulatory Risks (Item 1A, quoted)
- The limited number of patients who have the diseases for which our product candidates are being studied, has made it more difficult to enroll patients in our clinical trials, which could delay or prevent the start of clinical trials for our product candidates.
- The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidates in clinical trials, and any other product candidates that may advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval.
- We are developing and may continue to develop our programs in combination with other therapies, which exposes us to additional risks.
- We are currently investigating SLS009 in combination with aza/ven in a Phase 2 clinical trial and we may continue to develop clinical candidates in combination with one or more currently approved cancer therapies or therapies currently in clinical development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 150.27 | ▼ 1.9% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt